Last updated: 23 June 2023 at 4:06pm EST

James Bristol Net Worth




The estimated Net Worth of James Arthur Bristol is at least $303 Thousand dollars as of 19 April 2021. James Bristol owns over 7,000 units of Deciphera Pharmaceuticals Inc stock worth over $43,503 and over the last 7 years he sold DCPH stock worth over $0. In addition, he makes $259,448 as Independent Chairman of the Board at Deciphera Pharmaceuticals Inc.

James Bristol DCPH stock SEC Form 4 insiders trading

James has made over 12 trades of the Deciphera Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of DCPH stock worth $27,650 on 19 April 2021.

The largest trade he's ever made was exercising 25,000 units of Deciphera Pharmaceuticals Inc stock on 1 November 2019 worth over $47,250. On average, James trades about 9,422 units every 38 days since 2017. As of 19 April 2021 he still owns at least 1,700 units of Deciphera Pharmaceuticals Inc stock.

You can see the complete history of James Bristol stock trades at the bottom of the page.





James Bristol biography

Dr. James Arthur Bristol Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Bristol has served as a member of our Board of Directors since August 2007, as Chairperson since February 2015 and as co-Chairperson from September 2007 to February 2015. Dr. Bristol has also served as Chairperson of the Compensation Committee since September 2017. Dr. Bristol worked for 32 years in drug discovery, research and preclinical development at Schering-Plough Corporation, Parke-Davis, and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007, Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development, where he oversaw 3,000 scientists at seven Pfizer sites as they produced an industry leading number of drug development candidates in 11 therapeutic areas. In 2009, Dr. Bristol joined Frazier Healthcare Ventures as a Senior Advisor. He has served as director of Ignyta, Inc. from 2014 to 2018, Erasca, Inc. since 2018, and Cadent Therapeutics, Inc. since 2011. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.

What is the salary of James Bristol?

As the Independent Chairman of the Board of Deciphera Pharmaceuticals Inc, the total compensation of James Bristol at Deciphera Pharmaceuticals Inc is $259,448. There are 15 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.



How old is James Bristol?

James Bristol is 73, he's been the Independent Chairman of the Board of Deciphera Pharmaceuticals Inc since 2015. There are no older and 19 younger executives at Deciphera Pharmaceuticals Inc.

What's James Bristol's mailing address?

James's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.

Insiders trading at Deciphera Pharmaceuticals Inc

Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.



What does Deciphera Pharmaceuticals Inc do?

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.



What does Deciphera Pharmaceuticals Inc's logo look like?

Deciphera Pharmaceuticals Inc logo

Complete history of James Bristol stock trades at Deciphera Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
19 Apr 2021 James Arthur Bristol
Director
Option 7,000 $3.95 $27,650
19 Apr 2021
1,700
12 Apr 2021 James Arthur Bristol
Director
Option 14,700 $3.95 $58,065
12 Apr 2021
14,700
15 Jan 2021 James Arthur Bristol
Director
Option 7,000 $3.95 $27,650
15 Jan 2021
7,000
9 Oct 2020 James Arthur Bristol
Director
Option 23,541 $1.89 $44,492
9 Oct 2020
23,541
9 Jul 2020 James Arthur Bristol
Director
Option 23,541 $1.89 $44,492
9 Jul 2020
23,541
9 Apr 2020 James Arthur Bristol
Director
Option 23,542 $1.89 $44,494
9 Apr 2020
23,542
2 Jan 2020 James Arthur Bristol
Director
Option 23,542 $1.89 $44,494
2 Jan 2020
7,989
1 Nov 2019 James Arthur Bristol
Director
Option 25,000 $1.89 $47,250
1 Nov 2019
25,000
13 Aug 2019 James Arthur Bristol
Director
Option 25,000 $1.89 $47,250
13 Aug 2019
25,000
14 Feb 2019 James Arthur Bristol
Director
Option 18,883 $1.89 $35,689
14 Feb 2019
17,782
12 Feb 2019 James Arthur Bristol
Director
Option 3,522 $1.89 $6,657
12 Feb 2019
2,922
5 Feb 2019 James Arthur Bristol
Director
Option 2,595 $1.89 $4,905
5 Feb 2019
2,595


Deciphera Pharmaceuticals Inc executives and stock owners

Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: